This study maintains GIST430 (p53 WT), GIST882, and GIST-T1 (p53 MT), which can serve as experimental models in GIST preclinical testing for developing potential therapeutics targeting p53 or related pathways. Here, TP53 is linked to gastrointestinal stromal tumor.